Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.73 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098967 | 0.92 | P2RX7 (0.73) | P2RX7RAB9AHPGD | |
| SCHEMBL1099968 | 0.89 | P2RX7 (0.79) | P2RX7HPGD | |
| SCHEMBL1099997 | 0.88 | P2RX7 (0.77) | P2RX7RAB9ANPC1 | |
| SCHEMBL1108383 | 0.87 | P2RX7 (0.70) | P2RX7 | |
| SCHEMBL1098957 | 0.87 | P2RX7 (0.67) | P2RX7HPGD | |
| SCHEMBL1099750 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL1100619 | 0.84 | P2RX7 (0.63) | P2RX7RAB9ANPC1GRIN2BHPGD | |
| SCHEMBL1099761 | 0.84 | P2RX7 (0.71) | P2RX7HPGD | |
| SCHEMBL1099849 | 0.84 | P2RX7 (0.65) | P2RX7RAB9ANPC1HPGD | |
| SCHEMBL1099787 | 0.83 | P2RX7 (0.62) | P2RX7RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153809-B2 | Dihydropyridone ureas as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | P2RX7 5/4885PANK3 1586/4885RAB9A 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.